drugset / Trial / NCT00153608

WT1 Peptid Vaccination in Carcinomas

NCT00153608

Phase 2 Unknown 25 enrolled Charite University, Berlin, Germany
Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF

Timeline

Start
2004-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject WT1 126-134 peptide Peptide